TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06023732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation and emotion-focused interventions
Description: Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation and emotion-focused interventions
Description: Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
Study: NCT04816058

Intervention type: BEHAVIORAL
Intervention: Determining the level of ankle instability
Description: Ankle instability

Intervention type: BEHAVIORAL
Intervention: Determining the level of ankle instability
Description: Ankle instability
Study: NCT05505409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucocorticoid and immunosuppressant
Description: Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucocorticoid and immunosuppressant
Description: Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
Study: NCT04836247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosing Recovery: A Decision Aid and Toolkit
Description: Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Participants will be able to choose from several guided meditations to promote mindfulness
Study: NCT04883814

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluoroestradiol PET/CT
Description: Estrogen receptor targeted imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluoroestradiol PET/CT
Description: Estrogen receptor targeted imaging
Study: NCT05753163

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HAIC-FOLFOX combined with Sintilimab and Regorafenib
Description: HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
Study: NCT05318911

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novel yogurt drink
Description: Novel ovine yogurt drink containing polar lipids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink (skimmed milk)
Study: NCT05321251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: see arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tarsorrhaphy
Description: see arm description
Study: NCT04928118

Intervention type: OTHER
Intervention: Evaluate the blood flow and pressure into kidneys
Description: Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content.
Study: NCT06023043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
Study: NCT04967339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot deformity correcting insoles
Description: Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral wedge insoles
Description: Lateral wedge insoles
Study: NCT05564806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH004
Description: All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
Study: NCT04741672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing guidance after discharge routine procedure and calling one week after discharge.
Description: Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge routine procedure.
Description: Discharge routine procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge routine procedure.
Description: Discharge routine procedure.
Study: NCT05774847

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05094141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality game
Study: NCT05697796

Intervention type: PROCEDURE
Intervention: Two different surgical methods
Description: SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
Study: NCT05763030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Sleep Well, Bee Well (SWBW)
Description: The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
Study: NCT06202352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Yoga
Description: The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
Study: NCT04373330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: There will be 14 sessions delivered over the course of 6 months; materials consist of CHW lesson plans, participant workbooks, and the DVD series. These materials will be adapted for use in HELP-VM and will include information on migraine and its management as well as mental health resources available to Veterans for common illnesses like depression and post-traumatic stress disorder and modifying physical activity recommendations for Veterans with limited mobility.
Study: NCT05174169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signatera test
Description: Central ctDNA testing for all patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera test
Description: Central ctDNA testing for all patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signatera test
Description: Central ctDNA testing for all patients
Study: NCT06117124

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Digital X-Ray Radiogrammetry
Description: An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
Study: NCT05125328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
Study: NCT05174169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera test
Description: Central ctDNA testing for all patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 3-6 month
Description: Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX 3 month
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
Study: NCT06117124

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Digital X-Ray Radiogrammetry
Description: An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Ultrasound (QUS)
Description: The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Ultrasound (QUS)
Description: The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
Study: NCT06427356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVAIL Interdisciplinary Team
Description: Patient meets simultaneously with an interdisciplinary team (IDT) five pain specialists and develops an individualized treatment plan based on Whole Health. Participants receive five months of coaching calls then return six months later for a follow-up visit with the IDT.
Study: NCT04943432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: 8 sessions of harm reduction-focused Behavioral Activation for Substance Use
Study: NCT06418451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrospinous ligament fixation (SLFF)
Description: SSLF is a surgical procedure used to treat vaginal apex prolapse by fixing the vaginal apex to the right sacrospinous ligament. The procedure involves marking and incising the posterior vaginal wall, dissecting the vaginal rectal space, and placing sutures on the outer one-third of the ligament. These sutures connect the vaginal apex to the attachment point of the right uterosacral ligament. Anterior/posterior vaginal wall repair procedures can be performed if needed, without using implant materials. SSLF provides enhanced support for the vaginal apex.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified ischial spinous fascia fixation (modified ISFF)
Description: The modified ISFF procedure involves making a midline incision along the posterior fornix of the vagina, exposing the ischial spine fascia. Two sutures are placed around the ischial spine and passed through the mucosa of the anterior and posterior vaginal walls, lifting the vaginal apex and anterior wall towards the spine. The procedure also allows for additional anterior/posterior vaginal wall repair if necessary, without using implant materials.
Study: NCT05174169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 6 month
Description: Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
Study: NCT05862090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2301
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2301
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once a day per period.
Study: NCT05683002

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia supplementation
Description: As described in experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose supplementation
Description: As described in placebo comparator arm
Study: NCT05797597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 300 Mg Oral Tablet
Description: 8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
Study: NCT06262243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electric blankets
Description: While the patient is in surgery; An electric blanket will be placed under the bed mattress, and the bed will be placed on the electric blanket.~The bed sheet will be laid, and the blanket used in the clinic will be laid on top of the bed sheet.~-The electric blanket will be turned on at hot setting 20 minutes before the patient leaves the surgery. After the mother is placed in a heated bed, the electric blanket will be unplugged when the temperature reaches 36.5.
Study: NCT06192680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan
Description: 70 mg/m² IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m² PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV
Study: NCT05347303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finding-oriented orthopedic manual therapy treatment combined with foam roller
Description: Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
Study: NCT04809220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antihyperglycemics
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemics
Description: Administered orally
Study: NCT05347303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam roller treatment
Description: Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
Study: NCT05409937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-saturated Improved Hot Weather Combat Uniform
Description: Water-saturated Improved Hot Weather Combat Uniform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-saturated Army Combat Uniform
Description: Water-saturated Army Combat Uniform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-saturated Army Combat Uniform
Description: Water-saturated Army Combat Uniform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-saturated Army Combat Uniform + Silk Weights
Description: Water-saturated Army Combat Uniform + Silk Weights
Study: NCT06262217

Intervention type: DEVICE
Intervention: Mobile MRI scanner
Description: Use of mobile MRI scanner in patients with suspected or confirmed acute stroke (including Transient Ischaemic attacks)
Study: NCT06236490

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Oxygen Level Test
Description: The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Wingate Anaerobic Test
Description: WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth \< 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
Study: NCT05445492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM Device
Description: The CPM device and reference device are used simultaneous to validate the CPM device.
Study: NCT05114135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteo3 ZP Putty
Description: Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.